Clinical Trial Update: FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating FOLFOX/Bevacizumab with or without MK-0646 for metastatic colorectal cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• MK-0646 (dalotuzumab)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: WITHDRAWN